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Key Clinical Message
A novel homozygous long-range deletion of the CYP17A1 gene abolished pro-
tein expression and caused the severest form of 17-hydroxylase deficiency in
one kindred of a Turkish family. The affected subjects presented with 46,
XY sex reversal and 46,XX lack of pubertal development as well as severe hyper-
tension.
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Introduction
Childhood hypertension and disordered pubertal devel-
opment are conditions with a broad range of possible
underlying diseases. A common cause for both may be
a disorder of steroid biosynthesis which affects both
mineralocorticoid (MC) and sex steroid (SS) production
[1, 2]. Patients with complete or partial, combined
17a-hydroxylase/17,20-lyase deficiency usually present in
childhood to adolescence with hypertension and hypo-
kalemia due to increased MC production, with blunted
stress response due to inadequate cortisol production,
and with 46,XY disordered sex development (DSD) and
lack of sexual maturation due to SS deficiency [1, 2].
Most mutations of the CYP17A1 gene cause com-
bined 17a-hydroxylase/17,20-lyase deficiency [1, 2], but
a few cases of isolated 17,20-lyase deficiency have
been reported in whom only SS production is affected
[3–6].
Cytochrome P450c17 (OMIM 609300) is an essential
steroidogenic enzyme for glucocorticoid (GC) and SS
biosynthesis. It possesses dual activity. The 17-hydroxylase
activity converts pregnenolone to 17-hydroxy-preg-
nenolone and progesterone to 17-hydroxy-progesterone.
The 17,20-lyase activity converts 17-hydroxy-preg-
nenolone to dehydroepiandrosterone, but has only little
catalytic activity to convert 17-hydroxy-progesterone to
androstenedione [1, 2, 7]. Lack of its activities results in
SS and relative cortisol deficiency, and overproduction of
MC precursors with some GC activity [1, 2].
We report a novel homozygous long deletion in the
CYP17A1 gene, which causes nonexpression of protein
and thus the severest form of 17-hydroxylase deficiency in
a Turkish family of Kurdish origin.
ª 2015 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
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Case Report
The index patient (IV.2, Fig. 1A) was first seen by a gen-
eral practitioner in a remote area of Turkey for epistaxis
at 12 years of age. At that time she was noted to have
severe hypertension and was prepubertal. Clinical and
minimal biochemical work-up (data not available) indi-
cated that the underlying cause could be 17-hydroxylase
deficiency. Treatment with physiologic dose of hydrocor-
tisone (8–10 mg/m2/day) was recommended. Her two sis-
ters were clinically investigated at age 10 (IV.3) and 7
(IV.4) and were suspected to suffer from the same condi-
tion (Fig. 1A). Adherence to treatment was difficult and
follow-up lost. Five years after initial presentation, lack of
pubertal development brought them back to medical
attention. At this time, specific clinical and biochemical
investigations were performed (Table 1) confirming the
diagnosis of 17-hydroxylase deficiency (Fig. 1B). Addi-
tional tests revealed that the youngest sister (IV.4) was
46,XY and had no uterus and gonadal tissue on pelvic
MRI (Table 1). According to her medical history, she had
an operation for bilateral inguinal hernia when she was
an infant, but the parents, who are first-degree cousins
(III.7 and III.8; Fig. 1A), do not recall whether she was
gonadectomized. The family history is remarkable for two
unmarried female cousins (IV.5, IV.6; Fig. 1A) who
receive hydrocortisone treatment for adrenal disease but
do not wish to be further investigated.
Urine samples of patients IV.2 and IV.4 were analyzed
by gas chromatography/mass spectrometry and revealed
high corticosterone metabolites and low progesterone,
deoxycortisol, androgen, and estrogen metabolites con-
firming a combined 17a-hydroxylase/17,20-lyase defi-
ciency (Fig. 1B). Leukocyte genomic DNA was prepared
from the parents and the four siblings consenting for
genetic analysis. CYP17A1 gene analysis was first per-
formed by an exon-by-exon approach as described [8]
but revealed no PCR products for exons 1–6 in the three
affected subjects suggesting a big deletion. Thus, a long-
frame PCR with primers located at 3 kb of the
CYP17A1 promoter (50-AGT CCT CCT TTA TGG GAC
TCT GA) and at c.2007-1198 in exon 7 (50-CAC TCC
TTC TCA TTG TGA TGC AG) was performed showing
the exact architecture of the large deletion of the
CYP17A1 gene cutting out the promoter, the transcription
start site, and six exons/introns (Fig. 1C). The exact
boundaries of the deletion were revealed by direct
sequencing (Fig. 1C; GenBank NG_007955.1). This dele-
tion, covering more than 7 kb (7471 bp), corresponds to
two long deletions with a 29-bp fragment of IVS2 in
between (Fig. 1C). The first deletion c.-2011_436+119del
(4238 bp) extends from 2011 to IVS2 and the second
c.437-93_1140-262del (3233 bp) from IVS2 to IVS6. As
this deletion cuts out the gene transcription start site, it
causes a complete knockout of CYP17A1.
Discussion
This “two-in-one” deletion is the longest deletion
detected in the CYP17A1 gene [9]. Previously described
deletions are 1–25 bp long or small or larger indels. How-
ever, none is located in the promoter region or involves
the transcription start site; thus all of them produce some
sort of a CYP17A1 protein [9]. The most prevalent
CYP17A1 deletion is D487_F489del (c.1459_1467del-
GACTCTTTC), which has been detected in many patients
with 17a-hydroxylase/17, 20-lyase deficiency, mostly of
Chinese origin [10–19]. Among people of European
ancestry, the most common mutation is a 4-bp C-termi-
nal duplication (following Ile479) among Dutch Frieslan-
ders and their descendants [20]. The relevance of the
unique large indel mutation (518-bp deletion together
with a 469-bp insertion) is not clear [21]. This mutation
expanding from exons 2 and 3 was identified in a 46,XY
female patient with severe combined 17a-hydroxylase/17,
20-lyase deficiency, with two affected 46,XX sisters [21].
Figure 1. Steroid profiling and genetic work-up of the family with a novel CYP17A1 deletion. (A) Family tree showing karyotype, genotype (29,
39, and 59 – number of healthy individuals; wt, wild type; del, deletion), and phenotype. (B) Gas chromatography/mass spectrometry profile of
24-h urine from a control and patient IV.4. Arrows indicate corticosterone metabolites THA, THB, and 5a-THB (in bold), which are elevated in
CYP17 deficiency. Note also overall low androgens. Andro, androsterone; Etio, etiocholanolone; DHA, dehydroepiandrosterone; 11-oxo-etio, 11-
oxo-etiocholanolone; 11b-OH-andro, 11b-hydroxyandrosterone; 17-HP, 17hydroxypregnanolone; 11b-OH-etio, 11b-hydroxyetiocholanolone; PD,
pregnanediol; PT, pregnanetriol; 5-AT, 5-androstene-3b, 16a, 17b-triol; THS, tetrahydrodeoxycortisol; THDOC, tetrahydrodeoxycorticosterone;
PTone, 11-oxo-pregnanetriol (or pregnanetriolone); MP(ISTD), medroxyprogesterone (recovery standard); THE, tetrahydrocortisone; THA,
tetrahydro11-dehydrocorticosterone; THB, tetrahydrocorticosterone; 5a-THB, 5a-tetrahydrocorticosterone; THF, tetrahydrocortisol; 5a-THF,
5a-tetrahydrocortisol; SS(ISTD), stigmasterol (standard for derivatization and chromatography); 20b-DHF, 20b-dihydrocortisol; 20a-DHF,
20a-dihydrocortisol. (C) Genetic analysis of the identified deletion. The analytic strategy and location of the identified deletion is shown in a
diagram showing the CYP17A1 gene. PCR products of the long amplification PCR are depicted. The lower band corresponds to double deletion
and the upper band to the wild-type situation. All patients are homozygous for the deletion, the parents are heterozygous whereas one sibling is
genetically wild-type on both alleles (wt, wild type; del, deletion). The original sequence (reverse) of the CYP17A1 gene with the 2-deletion
breakpoints and the conserved IVS2 sequence detected in the parents and the three affected siblings are also shown.
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Other common mutations include point mutations
W406R and R362C among Brazilians of Spanish and Por-
tuguese ancestry, respectively [22]. However, the exact
frequency of any CYP17A1 mutation in any population
has not been assessed so far.
In the reported family the index patient was 46,XX and
presented with hypertension and without pubertal devel-
opment manifesting at the age of puberty, which is typical
for affected 46,XX individuals with CYP17 deficiency.
However, bilateral inguinal hernia (likely containing male
gonads) in the affected individual IV.4 in infancy should
have raised suspicion of a DSD situation. Taking this into
account, this patient could have been investigated in
infancy for a 46,XY DSD situation with normal male
internal organs (without M€ullerian structures) pointing to
a disorder of androgen synthesis or action. Thus her diag-
nosis was obviously missed at a young age. 46,XY individ-
uals with severe 17-hydroxylase deficiency are basically
not able to produce testosterone and thus present with a
female phenotype of the external genitalia at birth. The
gonads may be found in the genital folds, inguinal or
may be located intra-abdominally [1]. Some pubertal
development (breast and pubic hair) may be seen in 46,
XX patients with partial activity of CYP17A1 [2, 23], and
was even seen at age 15 and 18 years in our 46,XX
patients with a complete loss of CYP17A1. This indicates
that some androgens may be produced in the periphery
from precursors and other enzymes. However, to our
knowledge, the detailed metabolome of CYP17 deficiency
naming those active intermediates and alternate pathways
has not been described.
From this experiment of nature we learnt that
CYP17A1 is not crucial for survival, even though it is
essential for cortisol biosynthesis in the human adrenals.
Lack of CYP17A1 for cortisol production can be compen-
sated by enhanced production of corticosterone, which
also has GC activity and is in fact the active GC in
rodents, which lack CYP17A1 expression in their adrenals
[24]. Late manifestation of hypertension is also known in
children with 11b-hydroxylase deficiency due to elevated
deoxycorticosterone [1]. Levels of MCs are physiologically
higher in young children, who may also have higher
blood vessel plasticity, explaining why they may not man-
ifest with hypertension early. On the other hand, blood
pressure is often not measured and hypertension therefore
remains underdiagnosed in childhood.
Treatment of P450 deficiency includes physiologic
replacement of GC and sex hormones (at puberty). To
control blood pressure, antihypertensive drugs may be
necessary. Affected 46,XY individuals with ambiguous
genitalia may desire surgical repair.
In summary, we report a novel long-range CYP17A1
deletion in several, both 46,XX and 46,XY, family mem-
bers with typical clinical manifestations of severe 17-hy-
droxylase deficiency – a rare genetic disorder of steroid
biosynthesis with manifestation in childhood.
Patient Consent
Informed consent was obtained from all the subjects of
the study.
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